Thyrotropin-releasing hormone (TRH; also known as protirelin) is a compact tripeptide (pyroglutamyl-histidyl-proline amide) endogenously produced by hypothalamic neurons and distributed across multiple brain regions. In experimental neuroendocrinology, TRH is widely used as a mechanistic probe to interrogate hypothalamic–pituitary signaling, peptide GPCR activation, and downstream second-messenger dynamics. Beyond endocrine axis biology, TRHergic circuitry has been examined in preclinical models of cerebellar synaptic plasticity, autonomic regulation, and integrative brainstem control of cardio-respiratory outputs.

Source: PubChem

Sequence: Pyr-His-Pro
Molecular Formula: C₁₆H₂₂N₆O₄
Molecular Weight: 362.39 g/mol
PubChem CID: 638678
CAS Number: 24305-27-9
Synonyms: Protirelin, Thyroliberin, Lopremone, Relefact

TRH is a compact, polar peptide with rapid susceptibility to enzymatic turnover in biological matrices. In mechanistic workflows, TRH is applied as a receptor ligand to quantify TRH receptor (TRHR) signaling and downstream readouts such as phospholipase C activation, inositol phosphate production, intracellular Ca²  mobilization, and phosphorylation/dephosphorylation-dependent pathway changes in relevant model systems.

• Neuroendocrine signaling models: TRH is used as a probe for hypothalamic–pituitary axis circuitry, TRHR pharmacology, and hormone-release pathway mapping in cell-based, ex vivo, and in vivo animal systems.
• Cerebellar synaptic plasticity: TRH has been studied as a modulatory input in rodent models investigating cerebellar long-term depression (LTD) and associated motor-learning phenotypes.
• Autonomic network physiology: In rodent preparations, TRH has been evaluated for effects on integrative brainstem outputs, including experimentally measured respiratory and cardiovascular parameters.
• Analog comparison studies: TRH is frequently benchmarked against metabolically stabilized analogs (e.g., taltirelin) to evaluate duration-of-action and signaling persistence in preclinical assay systems.

TRH activates TRH receptors (TRHR family GPCRs), which are commonly associated with Gq/11-mediated phosphoinositide signaling. Canonical downstream events include phospholipase C activation, generation of IP3 and DAG, Ca2 -dependent signaling, and protein kinase activation with measurable phosphorylation state changes in target proteins. In neuronal circuits, TRHergic signaling has been examined for its capacity to modulate excitability and synaptic integration through activity-dependent signaling cascades.

In cerebellar research contexts, TRH has been evaluated as a neuromodulator influencing LTD-related molecular pathways and procedural learning behaviors in rodents. In autonomic physiology models, TRH has been investigated in relation to brainstem network activity that shapes respiratory and cardiovascular outputs under controlled experimental conditions.

Cerebellar LTD and motor learning (rodent models): Genetic and experimental paradigms have been used to evaluate the contribution of TRH signaling to cerebellar LTD and performance across repeated motor task trials in mice^[5].

Knockout mice treated with TRH learned much faster after four trials, with time before falling from rotating rod being nearly twice that of untreated mice. This shows improved rates of motor learning
Source: PubMed

Respiratory physiology (anesthetized rat preparations): TRH and TRH analogs have been assessed in rodent paradigms quantifying ventilation under pharmacologically induced respiratory depression^[7].

Hemodynamic stress models (rat hemorrhage): Metabolically stabilized TRH analogs (e.g., taltirelin) have been examined in acute rat models measuring arterial pressure, respiratory parameters, and blood gas/acid–base indices following controlled hemorrhage^[8].

Neuroanatomical/circuit context: Reviews summarize TRH localization, receptor distribution, and proposed neuromodulatory roles in cerebellar and broader CNS networks relevant to plasticity and motor coordination research^[6].

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Prof. Walter Pierpaoli was born in 1934 in Milan. He graduated with honors in Medicine and Surgery in 1960. After a major in Cardiology and a period as Assistant Hospital and practical activity (Medical Office), taught as an Assistant at the Institute of General Pathology, University of Milan, conducting research in biophysics (photodynamic effect) and taking advantage of a scholarship of the Atomic Energy Commission of the United States. Prof. Pierpaoli promoted first by many years the medical interdisciplinary now called “Neuroimmunomodulation”, to which now devote thousands of researchers. He devised, based on his original research, interventions against diseases of aging and is conducting for many years in Seattle, in the United States, with a group of researchers at the well-known Fred Hutchinson Cancer Research Center, research started in 1978 and based on a new method of transplants that can modify the immune system and prevent the organ rejection. This project, protected by worldwide patents, is in a very advanced stage of development and will provide the first clinical internships widespread pathologies, including diabetes and cancer. Prof. Pierpaoli has published over 140 scientific papers experimental, published in the best scientific journals such as Nature, (7 items), the Journal of the National Cancer Institute – USA, Proceedings of the National Academy of Sciences – USA and many others.

Notable achievements:

• Founded the Stromboli Conference on Aging and Cancer in Italy; 2004
• Director of Biancalana – Masera Foundation for the aged in Ancona Italy.
• Granted the award for Excellence in Anti-Aging Medicine, from the Monte Carlo Antiaging Conference ™

Author of the following books:

• Reversal of Aging – Resetting the Pineal Clock
• Reversal of Aging – Myth and Reality: Beyond the man made barriers
• The Aging Clock
• The Melatonin Miracle
• Physiological Senescence and Its Postponement: Theoretical Approaches and Rational Interventions
• Neuroimmunomodulation: Interventions in Aging and Cancer

Thyrotropin-releasing hormone (TRH) aroused their interest when they were engaged in related experiments, so they decided to study its effects on organs, tissues, and aging-related metabolic and hormonal markers when administered in acute or chronic (oral) doses at various time points in its cyclic circadian pattern.

Prof. Walter Pierpaoli is being referenced as one of the leading scientists involved in the research and development of [peptide name here]. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor.

1. L. B. Marangell et al., “Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients,” Arch. Gen. Psychiatry, vol. 54, no. 3, pp. 214–222, Mar. 1997. [PubMed]
2. R. Bunevicius and V. Matulevicius, “Short-lasting behavioural effects of thyrotropin-releasing hormone in depressed women: results of placebo-controlled study,” Psychoneuroendocrinology, vol. 18, no. 5–6, pp. 445–449, 1993. [PubMed]
3. A. M. Callahan et al., “Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics,” Biol. Psychiatry, vol. 41, no. 3, pp. 264–272, Feb. 1997. [PubMed]
4. M. P. Szuba et al., “Rapid antidepressant response after nocturnal TRH administration,” J. Clin. Psychopharmacol. [PubMed]
5. M. Watanave et al., “Contribution of Thyrotropin-Releasing Hormone to Cerebellar Long-Term Depression and Motor Learning,” Front. Cell. Neurosci., 2018. [PubMed]
6. N. Shibusawa et al., “Thyrotropin-releasing hormone (TRH) in the cerebellum,” Cerebellum, 2008. [PubMed]
7. J. D. Boghosian et al., “Intravenous and Intratracheal Thyrotropin Releasing Hormone…,” J. Pharmacol. Exp. Ther., 2018. [PubMed]
8. H. Asai et al., “Reversal of hemorrhagic shock in rats…,” J. Recept. Signal Transduct. Res., 2011. [PubMed]
9. E. Fliers et al., “Decreased hypothalamic thyrotropin-releasing hormone gene expression…,” J. Clin. Endocrinol. Metab., 1997. [PubMed]
10. W. Pierpaoli, “Aging-reversing properties of thyrotropin-releasing hormone,” Curr. Aging Sci., 2013. [PubMed]
11. A. M. Mellow et al., “Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer’s disease,” Psychopharmacology, 1989. [PubMed]
12. L. Luo et al., “Thyrotropin releasing hormone (TRH) in the hippocampus of Alzheimer patients,” J. Alzheimers Dis., 2002. [PubMed]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any disease or condition. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.